eragidomide (CC-90009)

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

GSPT1 degrader, Ubiquitin pathway modulator

Related drugs:

GSPT1 deletion	Acute Lymphocytic Leukemia	GSPT1 deletion	Acute Lymphocytic Leukemia	CC-90009 Sensitive: D – Preclinical CC-90009 Sensitive : D	CC-90009 Sensitive: D – Preclinical CC-90009 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + CC-90009 Sensitive: D – Preclinical quizartinib + CC-90009 Sensitive : D	quizartinib + CC-90009 Sensitive: D – Preclinical quizartinib + CC-90009 Sensitive : D

Associations
(2)